Intro
Noninvasive prenatal testing, often called NIPT or cell-free DNA screening, can be a reassuring and informative option in early pregnancy. It uses a blood sample from the pregnant person to analyze fragments of placental DNA circulating in maternal blood, estimating the chance that the fetus has certain chromosomal conditions. Many people hear that NIPT is “highly accurate,” and for some conditions, especially trisomy 21, it performs very well. Still, it is important to understand what accuracy means, when testing is most reliable, and why a screening result is not the same as a diagnosis.
If you are considering NIPT, waiting for results, or trying to interpret a “high-risk,” “low-risk,” or “no-call” report, you may feel anxious even if you are medically informed. The goal of this article is to explain the timing, strengths, and limitations of NIPT in clear clinical terms while emphasizing that individual decisions should be made with an obstetric clinician, maternal-fetal medicine specialist, or genetic counselor.
Highlights
NIPT can usually be performed from about 10 weeks of gestation, when the fetal fraction is more likely to be sufficient for analysis.
The test has very high sensitivity and specificity for trisomy 21, but performance is lower and more variable for some other chromosomal conditions.
NIPT is a screening test, not a diagnostic test; positive results should generally be confirmed with chorionic villus sampling or amniocentesis before irreversible decisions.
False positives, false negatives, and inconclusive results can occur because the DNA analyzed is primarily placental in origin, not directly fetal tissue.
Maternal factors, multiple gestation, vanishing twin, fetal fraction, and the specific condition being screened all influence the meaning of a result.
What NIPT is actually testing
NIPT analyzes cell-free DNA fragments in the pregnant person’s bloodstream. A portion of these fragments comes from the placenta and is often used as a proxy for fetal chromosomal status. This is why many clinicians prefer the term cell-free DNA screening: the sample is maternal blood, and the fetal component is usually placental DNA rather than DNA obtained directly from fetal cells.
Most standard NIPT panels screen for common autosomal aneuploidies: trisomy 21, associated with Down syndrome; trisomy 18, associated with Edwards syndrome; and trisomy 13, associated with Patau syndrome. Many tests also offer fetal sex prediction and screening for sex chromosome aneuploidies, such as monosomy X or Klinefelter syndrome. Some laboratories provide expanded screening for selected microdeletions or rare autosomal trisomies, but the clinical performance of these broader panels is more variable.
Because NIPT estimates probability rather than directly confirming fetal chromosomes, results are typically reported as low risk, high risk, increased risk, atypical, or no result. The exact wording varies by laboratory. A low-risk result can substantially reduce the likelihood of the screened conditions, but it does not rule out all genetic disorders, structural anomalies, single-gene conditions, or pregnancy complications.
Best timing: why many tests start at 10 weeks
Many NIPT platforms can be performed from approximately 10 weeks of gestation. This timing is not arbitrary. Early in pregnancy, the proportion of placental cell-free DNA in the maternal bloodstream, called the fetal fraction, may be too low for reliable analysis. As gestation advances, fetal fraction generally increases, improving the chance that the laboratory can generate an interpretable result.
Testing too early can increase the likelihood of a no-call or inconclusive result. This does not necessarily mean something is wrong, but it can create uncertainty and may require a repeat blood draw. Accurate pregnancy dating also matters. If ovulation occurred later than expected or the pregnancy is not as far along as estimated by last menstrual period, the fetal fraction may be lower than anticipated.
NIPT timing should also be considered alongside other first-trimester evaluations. Nuchal translucency ultrasound, first-trimester combined screening, early anatomy assessment, and routine prenatal labs may provide complementary information. For example, ultrasound can identify structural findings or dating discrepancies that NIPT alone cannot evaluate. Some patients choose NIPT because of its strong screening performance; others combine it with ultrasound-based assessment after discussing the benefits and limits with their care team.
How accurate is NIPT for common trisomies?
NIPT performs best for trisomy 21. In many clinical settings, sensitivity and specificity for trisomy 21 are very high, often above those of traditional serum screening. Sensitivity refers to how well a test identifies pregnancies affected by the condition; specificity refers to how well it identifies pregnancies not affected by the condition. High sensitivity reduces, but does not eliminate, the chance of a false negative. High specificity reduces, but does not eliminate, the chance of a false positive.
Performance for trisomy 18 is also generally strong, though often slightly lower than for trisomy 21. Performance for trisomy 13 tends to be lower and more variable. This variation reflects biological and technical factors, including differences in placental mosaicism, fetal fraction, and the relative rarity of the condition.
It is also essential to distinguish sensitivity and specificity from positive predictive value. Positive predictive value, or PPV, is the probability that a high-risk result truly represents an affected fetus. PPV depends heavily on the baseline chance of the condition, which is influenced by factors such as maternal age, gestational age, ultrasound findings, and prior screening results. A test can have excellent sensitivity and specificity but a modest PPV for rare conditions, especially in a lower-risk population.
Why a positive NIPT result needs confirmation
A high-risk NIPT result can be emotionally overwhelming, but it should not be treated as a definitive diagnosis. Diagnostic testing is usually needed to confirm fetal chromosomal status. The two main diagnostic options are chorionic villus sampling, typically performed in the first trimester, and amniocentesis, typically performed later. These tests analyze fetal or placental cells in a more direct way and can provide a karyotype, chromosomal microarray, or other targeted testing depending on the clinical question.
Confirmatory testing is especially important before making major pregnancy-management decisions. The reason is that NIPT may detect a placental chromosomal pattern that is not present in the fetus, a phenomenon known as confined placental mosaicism. It may also be affected by a vanishing twin, maternal chromosomal variation, maternal copy-number variants, organ transplant history, or, rarely, maternal malignancy. These are not common scenarios for every patient, but they illustrate why screening and diagnosis are different categories.
Genetic counseling can be very helpful after a positive, atypical, or inconclusive result. A counselor can explain the condition-specific PPV, review ultrasound findings, discuss diagnostic testing options, and help you think through next steps without pressure. This support can make a difficult waiting period feel more structured and less isolating.
False negatives and the meaning of a low-risk result
A low-risk NIPT result is reassuring for the specific conditions included in the screen, particularly when fetal fraction is adequate and the report is otherwise straightforward. However, low risk does not mean no risk. False negatives can occur, though they are uncommon for trisomy 21. Potential contributors include low fetal fraction, placental mosaicism, sample or laboratory factors, and biological differences between placental and fetal chromosomes.
Low-risk NIPT also does not exclude many other conditions. It does not replace a detailed anatomy ultrasound, which assesses fetal structures such as the heart, brain, spine, kidneys, abdominal wall, and limbs. It also does not screen for most single-gene disorders, neural tube defects, congenital infections, metabolic conditions, or all chromosomal rearrangements. Depending on the test, some triploidy, microdeletions, or rare chromosomal abnormalities may not be assessed or may be assessed with limited accuracy.
If ultrasound later shows a structural anomaly, growth concern, or other unexpected finding, clinicians may recommend additional evaluation even if NIPT was low risk. This can feel confusing, but it reflects the fact that different tests answer different questions.
No-call and low fetal fraction results
A no-call result means the laboratory could not provide an interpretable screening result. One common reason is low fetal fraction. Fetal fraction can be influenced by early gestational age, higher maternal body mass index, sample handling, medication or medical conditions, and characteristics of the placenta. Sometimes a repeat sample after one to two weeks yields a result because fetal fraction has increased.
In some contexts, low fetal fraction itself may be associated with an increased risk of certain aneuploidies or placental dysfunction, but interpretation depends on the laboratory method, gestational age, ultrasound findings, and the patient’s overall clinical picture. A no-call result should not be dismissed automatically, but it also should not be assumed to indicate an affected pregnancy.
Common next steps may include verifying gestational age, repeating NIPT, considering first-trimester or second-trimester screening, obtaining a targeted ultrasound, or discussing diagnostic testing. The best path depends on the reason for the no-call result, the patient’s preferences, and the degree of clinical concern.
Limitations in twins, IVF pregnancies, and expanded panels
NIPT can be used in many twin pregnancies, but interpretation is more complex. Fetal fraction is shared across the pregnancy, and if one twin is affected, the signal may be diluted. Determining which twin is affected may not be possible from screening alone. Vanishing twin, where a demised co-twin contributes residual cell-free DNA, can increase the chance of discordant or false-positive results.
In pregnancies conceived through IVF, including those with preimplantation genetic testing, NIPT may still be offered. However, PGT and NIPT evaluate genetic risk in different ways and at different stages. PGT assesses cells biopsied from an embryo before transfer, while NIPT evaluates placental cell-free DNA during pregnancy. Neither replaces diagnostic testing when definitive fetal chromosomal information is needed.
Expanded NIPT panels deserve special caution. Screening for microdeletions, rare autosomal trisomies, or genome-wide copy-number changes may detect clinically relevant findings, but the PPV is often lower than for trisomy 21 because these conditions are rarer. Expanded results can also create ambiguous counseling situations, including findings that may relate to the placenta or pregnant person rather than the fetus. A more comprehensive test is not always a clearer test.
How to interpret NIPT results in context
The most useful interpretation of NIPT combines the laboratory result with clinical context. Important factors include gestational age, fetal fraction, whether the pregnancy is singleton or multiple, maternal age, ultrasound findings, family history, prior pregnancy history, and what exact conditions the panel included. Even the same “high-risk” label can have different implications depending on which condition is flagged.
Before testing, it can help to ask what you want the information for and what you would do with different possible results. Some people want early reassurance. Others want time to prepare for a child with special medical needs. Some want to know whether diagnostic testing should be considered. There is no single emotionally correct approach, and patients should be supported without judgment.
Good pretest counseling should include what the test screens for, what it does not screen for, the possibility of no-call results, whether fetal sex or sex chromosome findings will be reported, and how positive results are confirmed. If you receive a result that feels frightening or unclear, contacting your obstetric clinician or a genetic counselor promptly is appropriate.
When to seek prompt professional guidance
- A high-risk NIPT result should be reviewed with an obstetric clinician or genetic counselor before drawing conclusions.
- Do not make irreversible pregnancy decisions based on NIPT alone without discussing confirmatory diagnostic testing.
- A no-call or low fetal fraction result may need follow-up, especially if gestational age is appropriate or ultrasound findings are concerning.
- New ultrasound abnormalities after a low-risk NIPT result still warrant medical evaluation.
- Twin pregnancy, vanishing twin, IVF history, or prior transplant can complicate interpretation and should be disclosed to the care team.
Tools & Assistance
- Schedule pretest or post-test counseling with a genetic counselor.
- Ask your prenatal clinician which conditions are included in the specific NIPT panel.
- Confirm gestational age with ultrasound if timing is uncertain.
- Request a written explanation of fetal fraction, PPV, and recommended follow-up.
- Discuss diagnostic testing options such as CVS or amniocentesis if results are high risk or unclear.
FAQ
When is the earliest NIPT can be done?
Many NIPT tests can be performed from about 10 weeks of gestation. Testing earlier may increase the chance of insufficient fetal fraction and an inconclusive result.
Is NIPT diagnostic?
No. NIPT is a screening test. A high-risk result indicates increased probability, but diagnostic testing such as CVS or amniocentesis is generally needed to confirm fetal chromosomal status.
Can NIPT be wrong?
Yes. False positives and false negatives can occur, although NIPT is highly accurate for trisomy 21. Accuracy varies by condition, fetal fraction, pregnancy type, and clinical context.
What does low fetal fraction mean?
Low fetal fraction means there was not enough placental cell-free DNA in the blood sample for reliable analysis. It may be related to early gestational age, maternal factors, placental factors, or technical issues.
Does a low-risk NIPT replace the anatomy scan?
No. NIPT screens for selected chromosomal conditions, while the anatomy ultrasound evaluates fetal structures and can detect findings unrelated to the screened aneuploidies.
Sources
- The New England Journal of Medicine — Noninvasive Prenatal Testing in the Clinical Setting
- Johns Hopkins Medicine — First Trimester Screening, Nuchal Translucency and NIPT
- Natera — Understanding Noninvasive Prenatal Testing (NIPT)
Disclaimer
This article is for informational purposes only and does not replace personalized medical advice. Consult your obstetric clinician, maternal-fetal medicine specialist, or genetic counselor about NIPT decisions and results.
